Article

Laser approved for hyperopia

The MEL 80 Excimer Laser (Carl Zeiss Meditec, Inc) has received premarket approval from the FDA for the treatment of hyperopia. This new indication complements the existing FDA approved applications of the surgical laser for myopia and astigmatism.

Dublin, CA-The MEL 80 Excimer Laser (Carl Zeiss Meditec) has received premarket approval from the FDA for the treatment of hyperopia. This new indication complements the existing FDA-approved applications of the surgical laser for myopia and astigmatism.

“Adding the hyperopia indication enables us to offer a complete range of treatment options to meet the demands of refractive surgeons and their patients,” said Ludwin Monz, president and chief executive officer of Carl Zeiss Meditec AG.

This excimer laser is indicated for use in primary LASIK treatments for the reduction or elimination of naturally occurring hyperopia in patients who are 21 years of age or older and who meet specific pre-treatment criteria.

Carl Zeiss Meditec AG also announced that Ulrich Krauss will be ending his 9-year membership on the company’s management board at the close of business April 12 to join the management of Carl Zeiss Vision International GmbH, a subsidiary of Carl Zeiss AG. Thomas Simmerer has been appointed to Carl Zeiss Meditec's management board to succeed Krauss as chief sales officer.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.